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Introduction
RNA interference (RNAi) has been proven to be a useful approach to treat various genetic diseases. It can down-regulate specific protein expression by silencing the activity of its targeted gene [1] [2] [3] [4] [5] . This approach exhibits significant promises for the development of a new class of molecular therapeutic drugs that interferes with disease-causing or -promoting genes, particularly those that encode so-called "non-druggable" targets not amenable to conventional therapeutics [6, 7] . However, many natural obstacles have to be overcome to achieve safe and efficient in vivo delivery of therapeutic RNAs [8] [9] [10] [11] . Thus, realizing the full potential of the RNAi-based therapeutics requires the development of an ideal carrier [4, [12] [13] [14] [15] that should be able to bind and condense RNA, provide protection against enzymatic degradation, selectively deliver RNA to target tissues, facilitate its intracellular uptake and escape from the endosome/lysosome, "on demand" RNA release, and finally promote efficient gene silencing [2, [16] [17] [18] .
In recent years, gold nanorods (GNRs) have attracted considerable attention for their unique properties in localized photothermal therapy [19, 20] , biosensing [21] , and molecular imaging [22] . Particularly, being an anisotropic, rod-shaped nanomaterial that is easily functionalized, GNR has begun to attract significant research interest in gene delivery [7, [23] [24] [25] [26] . Currently, two main strategies in GNR based gene delivery have been investigated: one is to use GNR as an active carrier where its photothermal properties are harnessed to selectively release the gene in a localized area. [23, 24, 26] . Another approach is the use of layer-by-layer (LBL) technique where biocompatible polymers or proteins (such as polyacrylic acid (PAA), polystyrenesulfonate (PSS) or bovine serum albumin (BSA)) are first over-coated on the CTAB-capped GNR surface, which is then functionalized with a layer of cationic polymer (such as polyethylenimine (PEI)) to switch GNR net surface charge to positive. The resulting carrier is used for gene condensation and subsequent intracellular gene delivery [27] [28] [29] [30] .
Although these two strategies can achieve laser-triggered gene release and/or reduced toxicity, they both have their own disadvantages. The first strategy cannot provide protection of the gene against degradation and the photothermal effect of GNR may cause cell death [23] . The limitation of the second strategy is that the carrier exhibited lower transfection efficiency than that of PEI/DNA complexes [27] . More recently, Ryan and co-worker have explored a poly-L-lysine peptide (PLL) capped gold nanoshell (GNS) for therapeutic oligonucleotide delivery and Cui's group has developed a RGD-conjugated dendrimer-modified GNR for gene delivery [7, 25] . Both approaches exhibit controlled gene release and improved delivery efficiency with low toxicity. Therefore, developing a "fine-tuned" surface for GNR is critical to improve its biocompatibility and application in gene/RNA delivery.
Polyethylenimine (PEI) has been regarded as the "gold" standard for gene delivery because it shows relatively high transfection efficiency due to its proton sponge effect and ability to protect DNA from enzymatic degradation [31, 32] . High molecular weight PEIs (such as 25-kDa PEI) are highly effective in gene transfection, but also have high cytotoxicity due to the high cationic density and lack of biodegradability [33] . Low molecular weight PEIs(such as 1.8-kDa PEI) have much lower cytotoxicity, but they cannot effectively condense DNA and display very poor gene transfection activity [33, 34] . In order to reduce the cytotoxicity and enhance carrier unpacking into the cytosol and/or nucleus, intracellular-cleavable disulfide-linked PEIs have been designed for gene delivery [35] [36] [37] [38] [39] . The disulfide linkage is stable during blood circulation [40] . Once inside cells, the cross-linking disulfide bonds are cleaved under the high concentration of reductive glutathione (GSH), making it favorable to unpack the PEI shell and release the infective nucleic acids [33, 41] . Therefore, a cleavable disulfide cross-linked PEI (DSPEI) was synthesized as the gene/RNA carrier with controlled-release property in response to intracellular reducing environments.
Integrin α v β 3 , an important biomarker often over-expressed on actively angiogenic endothelium and malignant glioma cell surfaces, plays a critical role in regulating tumor growth, metastasis and tumor angiogenesis [42, 43] . The cyclic RGD (arginine-glycine-aspartic acid) peptide (cRGD) can specifically bind with integrin α v β 3 [42, 44] . The high affinity interaction between the RGD peptide and over-expressed integrins on cancer cell surfaces has led to a widespread use of RGD peptide as ligand for integrin-targeted drug and gene delivery [44] [45] [46] . Thus, we have selected the RGD peptide as the targeting molecules for specific glioblastoma cell therapy.
We have recently developed an effective intracellular gene delivery system, RDG (RGD-PEG-DSPEI-GNR) that combine the advantageous properties of RGD-mediated specific targeting and intracellular stimuli-triggered degradability of DSPEI. This gene nanocarrier exhibited high transfection efficiency with low cytotoxicity. Herein, we report that the RDG could be used for targeted and intracellular small hairpin (sh)RNA delivery for effective RNAi therapy. The GSH triggered shRNA release, gene silencing efficiency and cytotoxcity of the RDG/shRNA complex nanoparticles were investigated at both cellular level and also in vivo mouse model using U-87 MG cells and tumor-bearing mice.
Materials and methods

Materials
RDG (RGD-PEG-DSPEI-GNR), DG (DSPEI-GNR) and RPG (RGD-PEI-25 KDa-GNR) conjugates were prepared in our lab as described previously [47] . and Phosphate buffer solution (PBS) were purchased from Gibco BRL (USA). Water was purified by distillation, deionization, and reverse osmosis (Milli-Q plus). All reagents were analytical grades and used without further purification.
The pGPU6/Neo-GFP22-shRNA-expressing pDNA that targets the sequence GCAGCACGACTTCTTCAAG was obtained from GenePharm Co. Ltd. (Shanghai, China) and purified with the Plasmid Maxi Kit (Qiagen GmbH, Hilden, Germany) in accordance with the manufacturer's instructions. The concentration of plasmid solution was determined by measuring the ultraviolet (UV) absorbance at 260 nm and the ratio of its optical density at 260 nm to 280 nm was in the range of 1.8 to 1.9.
Cell culture
The U-87 MG (human glioblastoma cell) cell line was generously donated by School of Pharmacy, Fudan
University. The U-87 MG cells expressing stable enhanced green fluorescence protein (U-87 MG-GFP cells)
were kindly provided by Center of Pharmaceutics, Shanghai Institute of Materia Medica. GFP-negative cells were cultured in DMEM containing 10% fetal bovine serum (FBS), 100 Units/mL penicillin G sodium and 100 g/mL streptomycin sulfate (complete DMEM medium). GFP-positive cells were grown in complete DMEM medium with 50 g/mL G418. Cells were maintained at 37 °C in a humidified and 5% CO 2 incubator. Cells grown to confluence were subcultured every other day after trypsinized with 0.25% trypsin-EDTA and diluted
(1/3) in fresh growth medium.
Animals
Male BALB/c mice aged 6 weeks (20-25 g) obtained from the Experimental Animal Center of Fudan University (Shanghai, China) and kept under a 12 h light/dark cycle at the Animal Care Facility with food and water ad libitum. The animals were acclimatized to the laboratory environment for at least 5 days prior to the experiments. All experiments were performed in accordance with the Animal Care and Welfare Committee of Fudan University and followed the animal care guidelines of the National Institutes of Health.
Preparation and characterization of RDGNR/shRNA complex nanoparticles
RGD peptide modified disulfide cross-linked polyethylenimine (DSPEI) capped GNR (RDG) was prepared according to our previous report [47] . The RDG/shRNA complex nanoparticles were prepared at seven different mass ratios ranging from 1 to 15 between the GNR nanocarriers and the GFP-shRNA. Briefly, various amount of RDG in water was added into the same volume of shRNA (50 g/mL in water). The mixture was then vortexed for 30 s and incubated at room temperature for 30 min.
The shRNA binding ability of the RDG nanocarriers was confirmed by agarose gel electrophoresis. The RDG-based complexes containing 0.5 g of shRNA at various mass ratios were loaded on 1% agarose gel in TAE buffer (40 mM Tris-HCl, 1 v/v% acetic acid, and 1 mM EDTA) containing 0.5 g/ mL EB and subjected to electrophoresis with a current of 100 V for 50 min. The resulting shRNA bands were visualized with a UV (254 nm) illuminator and photographed with a Vilber Lourmat imaging system.
For quantification of shRNA binding efficiency by the RDG nano-carrier, shRNA was fluorescently labeled with a nucleic acid stain YOYO-1 (excitation wavelength: 491 nm, emission wavelengths: 509nm) by mixing shRNA and YOYO-1 with a ratio of 1.5 nanomole dye molecule/100 g shRNA and incubated for 30 min at room temperature in the dark. The RDG/YOYO-1-labeled shRNA complexes were prepared and incubated at 37 °C for 30 min. Afterwards, the samples were centrifuged to remove the GNRs and collect the supernatants.
Fluorescence spectrophotometer (F-7000, Hitachi, Japan) was used to quantify the unbound shRNA in supernatants.
The zeta-potential of RDG/shRNA complexes were measured with Zetasizer NanoZS/ZEN3600 (Malvern Instruments, Herrenberg, Germany). The morphology and size of complexes were observed using a transmission electron microscope (TEM) (JEM-2100F, JEOL, Japan).
In vitro GSH triggered release studies
The GSH triggered reductive degradation of RDG-based complexes was also evaluated by agarose gel electrophoresis. RDG/shRNA complexes at different mass ratios were prepared as described above. After incubation for 30 min, GSH was added directly into the nanoparticle solution to reach a final concentration of 3 mM, which was comparable to the intracellular environment [48] . The nanoparticle solution was incubated at 37 °C for 30 min before agarose gel electrophoresis. For quantification of GSH triggered gene release from RDG/shRNA complexes, the RDG/YOYO-1-labeled shRNA complexes were prepared and treated with GSH at a concentration of 3 mM at 37 °C for 30 min. Afterwards, the samples were immediately centrifuged to remove the GNRs and collect the supernatants. Fluorescence spectrophotometer (F-7000, Hitachi, Japan) was used to quantify the released shRNA in supernatants. We quantified the fluorescence intensity of YOYO-1 due to YOYO-1-labeled shRNA released from RDG-based complexes.
Cell targeting of RDG/shRNA complex
The 
CLSM studies
Cell uptake and intracellular shRNA release of RDG/shRNA complexes was further analyzed by CLSM studies. U-87 MG cells were seeded at a density of 1×10 5 cells/well onto glass coverslips in a 12-well plate and allowed to attach for 24 h. Followed by removing the complete medium, the cells were incubated with the same reagents in intracellular GSH-triggered shRNA release studies. Then, the medium was aspirated, the cells were washed twice with PBS and treated with Hoechst 33342 (6 g/mL) and Lyso Tracker Red DND-99 (10 nmol/mL) at 37 °C for additional 20 min [49] . The extracellular fluorescence was quenched with 500 L of 0.4% trypan blue for 2 min. Followed by completely washing with PBS, the cells on coverslips were fixed with 500 L of 4% paraformaldehyde for 30 min, then the fixed cells were mounted in anti-fluorescence quenching mounting medium and sealed with slides. Cells were visualized under a confocal laser scanning microscope (CLSM) (TCS SP5, Leica, Germany) to observe the intracellular distribution of the YOYO-1 labeled shRNA.
In vitro RNAi and cell viability assays
RNAi experiment was performed with U-87 MG-GFP cells by using the GFP-shRNA as reporter gene. To evaluate the cytotoxicity of the vector, cells were seeded in 96-well plates at a density of 5×10 3 cells per well and allowed to attach overnight. After the medium was aspirated, the cells were treated with RDG at a concentration of 1, 5, 25, 50 and 75 g/ml, PEI 25-kDa at the concentration of 3.9 g/ml (the concentration of PEI 25-kDa at N/P ratio of 10) was used as a positive control. Followed by incubation for 48 h, the MTT assay was performed. Briefly, 20 l of 5 mg/ml MTT dissolved in PBS was added to each well. The cells were incubated for an additional 4 h at 37 °C and then the medium was discarded. Thereafter, 250 l of DMSO was added to each well to dissolve the formazan crystals. The absorbance was read on a microplate reader (Bio-Rad 680, USA) at a test wavelength of 570 nm and reference wavelength of 630 nm. The percentage of cell growth inhibition was calculated as follows: inhibitory rate = (A570 control − A570 sample )/A570 control × 100%.
To obtain a more convincing data about the cytotoxicity of RDG, cell viability was determined after the cells were treated with RDG/shRNA complex nanoparticles. Complexes with shRNA concentration of 3 g/mL at mass ratio of 10, 7.5 and 5 were added into the cells. MTT assays were performed similarly to the experiments mentioned above. RPG/shRNA complex at mass ratio of 5 and PEI/shRNA complex at N/P ratio of 10 were also used as control.
In vivo biodistribution and RNAi experiment
Subcutaneous tumors on the left flank of male nude mice were initiated by the injection of 2 ×10 6 viable U-87
MG-GFP cells in a volume of 0.2 mL. Tumors were allowed to reach about a volume of 150-200 mm 3 . Mice were randomly divided into two groups (n=5) and injected through the tail vein with RDG/shRNA and DG/shRNA complexes (both prepared at a mass ratio of 5, shRNA of 2 mg/kg), respectively. To investigate the biodistribution of GNR-based complex nanoparticles, the mice were sacrificed at 12 h after the i.v. injection.
The major organs including tumors were collected and completely lysed in aqua regia. Then, the solution was evaporated and suspended in an aqueous solution containing 1.0% aqua regia and the amounts of GNR in tissue samples were measured by ICP-MS (7500A, Agilent, USA).
For in vivo RNAi experiment, mice were randomly assigned to experimental and control groups (n=5).
Animals were injected through the tail vein with Saline, PEI-25 kDa/shRNA, DG/shRNA, and RDG/shRNA complexes (shRNA of 2 mg/kg), respectively. After 48 h, the mice were sacrificed. The tumors were taken out, washed with cold saline and observed using a Mulaurora™ in vivo fluorescence imaging system (ZKKS, China). 
Statistical analysis
The mean ± SD was determined for each treatment group. Student's t-test (two-tailed) or one-way analysis of variance (ANOVA) was applied to evaluate the significance. The statistical significance criterion P value was 0.05.
Results and discussion
Characterization of RDG/shRNA complexes
We have recently synthesized a targeted polymeric gene carrier, RD, by incorporating a RGD peptide into the disulfide cross-linked cationic polymer, DSPEI, via a hydrophilic polyethylene glycol (PEG) spacer (Fig. S1 ).
The DSPEI with a molecular weight of 22.5 kDa could be degraded under the intracellular reductive environment, but is relatively stable under physiological conditions. Monodisperse GNRs with an aspect ratio of 4.1 were synthesized by using the seed-mediated growth method (Fig. S2A) . In order to enhance stability, direct cell-specific targeting and controlled release "cargos" such as genes, the GNR surface was successfully functionalized with RDs via "round-trip" phase transfer ligand exchange (Fig. S3) . The phosphotungstic acid negative stained TEM images revealed that the GNRs were coated with a layer of RD conjugates without any shape change (Fig. S2B) . The RDG was stable even after 6 months of storage at high concentration (3×10 -8 M), and the plasmon peaks exhibited no significant changes in peak width or position, suggesting a good long-term stability. Zeta potential measurements further confirmed that the RDG had a high positive charge of 48.7±2.8 mV, indicating it could have a good gene loading capacity.
GNR-based shRNA complexes were prepared by adding the RDG solution into the shRNA solution in equal volumes. The shRNA concentration was kept constant. The concentration of RDG was adjusted according to the desired GNR/DNA mass ratios ranging from 1 to 15.
To be an effective gene vector, cationic polymers must be able to bind and condense shRNA into nanoparticles, which can then be taken up by cells. The shRNA binding and condensation capability of the synthesized RDG were investigated by gel retardation assay and shRNA bound efficiency measurements.
As shown in Fig. 1A and B, the RDG conjugates can completely retard shRNA migration and the shRNA nearly completely (98 %) condensed on the RDG nano carrier at a mass ratio of above 3, indicating that RDG exhibited strong capability to condense shRNA. Zeta potentials of the complexes under different mass ratios were measured and shown in Fig. 1C . At a mass ratio of above 3, all the complexes showed positive surface charges, suggesting that they were able to condense shRNA into complexes. The zeta potential of RDG /shRNA complexes showed a strong dependence on the mass ratios and decreased rapidly with the decreasing mass ratio. At a mass ratio of 5, the complex had a positive zeta potential of around + 20 mV. The complexes were further imaged by TEM after negative staining (Fig. 1D) . At pH 7.4 and mass ratio of 5, the DSPEIs and RNAs formed compact complexes of about 2 nm thick closely packed on the GNR surface, most likely due to strong electrostatic attractions between the positively charged polymers and negatively charged RNAs. The morphology and size of the GNR itself did not change during the complexes preparation process.
In vitro GSH-triggered shRNA release
RNA dissociation is one of the rate-limiting steps during RNA delivery, and the efficiency of dissociation is closely related to the overall efficiency of RNA interference [50] . In our previous report [47] , gel permeation chromatography (GPC) traces of DSPEI in the absence and presence of GSH clearly showed that the disulfide cross-linked DSPEIs were responsive to the reducing agent GSH (data not shown here). After incubation with GSH for 1 h at 37 °C, the average molecular weight of DSPEI decreased from 22.5 kDa to 2.1 kDa, which is very close to Mw of PEI only (1.8 kDa).
To assess the release of shRNA from RDG/shRNA complexes, the complexes were incubated in PBS (pH 7.4) in the presence of 3 mM GSH, which represented the simulated intracellular reducing environment.
GSH-triggered release of shRNA from the disulfide-containing GNR-complexes was visualized by gel electrophoresis ( Fig. 2A) . Compared with Fig.1A where the complexes were incubated in the extracellular physiological condition, the fluorescence bands clearly showed the presence of free shRNA in the supernatants of the RDG/shRNA complexes after incubation with 3 mM GSH (30 min), indicating that shRNAs were rapidly released. This is presumably due to the cleavage of disulfide bonds of DSPEI under the reductive conditions, producing much smaller PEIs that can no longer condense the RNAs. The shRNA release percentage for the GNR-complexes was further quantitated by fluorescence spectroscopy. As the mass ratio was decreased from 15 to 1.5, the released shRNA percentage was rapidly increased (Fig. 2B) . At a mass ratio of 5, the released shRNA was 46.6±3.7% under the above conditions. This result indicates that the complexes would be degraded after being internalized into the reductive intracellular environment and release their cargo efficiently. The RDG/shRNA complexes prepared at a mass ratio of 5 not only exhibited desirable shRNA binding and condensation ability, but also favorable shRNA release property upon GSH-stimulation, therefore, the mass ratio of 5 was chosen for the following assays.
Cell targeting of RGD modified GNR
Two different cell lines, the glioblastoma U-87 MG-GFP cells having over-expressed α v β 3 integrins, and the breast cancer cell line MCF-7 cells with low expression of α v β 3 integrins were used. To evaluate the specificity and targeting ability of RGD-modified GNR against α v β 3 integrins on the cells, the binding of RDG/shRNA and plain DG/shRNA with U-87 MG-GFP and MCF-7 cells were investigated using dark-field microscopy. As shown in Fig. 3A , the RDG/shRNA incubated MCF-7 cells exhibited a weak golden color, and similar negative result was also observed for DPGNR/shRNA treated U-87 MG-GFP cells. In contrast, the RGD-modified GNRs incubated U-87 MG-GFP cells exhibited a much stronger golden color, suggesting that the RDG/shRNA complex are taken up more efficiently by the U-87 MG-GFP cells, presumably via its surface over-expressed α v β 3 integrins. This was supported by incubation of the U-87 MG-GFP cells with RDG/shRNA complex in the presence of 1 mM free RGD peptides led to a significantly reduced cellular uptake of RGD-modified GNRs (Fig.   3Ad ). This result suggests that free RGD peptides can inhibit the uptake of the RGD-modified GNR through competitive binding to the tumor cell over-expressed α v β 3 integrins, leading to greatly reduced cellular uptake by blocking the effective α v β 3 integrins -mediated endocytosis [46, 48, 49] .
Furthermore, inductively coupled plasma mass spectrometry (ICP-MS) was used to confirm GNR cellular uptake. By quantifying the GNR number per cell, the highest column in chart shows a significant difference between the RDG/shRNA treated cells and the other three groups (Fig. 3B) . The U-87 MG-GFP cell uptake of the RDG/shRNA complex was approximately four-fold higher than that of plain complex, in good agreement with the above imaging results. This result demonstrated that the RGDs on the RDG/shRNA complex were readily accessible to α v β 3 integrin binding, and hence the RDG/shRNA complexes can be used as efficient, targeted intracellular gene carriers.
Intracellular monitoring of the release of shRNA triggered by GSH
It is well known that PEI can protect the gene from lysosomal nuclease degradation and facilitate endosomal escape to the cytoplasm via its proton sponge effect [51, 52] . The promotion of the shRNA release from the complexes into the cytoplasm is critical for high gene silencing efficiency. To confirm if the GSH-responsive gene delivery system based on RDG also works in cancer cells, flow cytometry was used to evaluate the release of YOYO-1 labeled shRNA from RDG/shRNA complex within the U-87 MG cells. As shown in Fig. 4A and B, cells treated with RPG/shRNA showed much lower fluorescence compared to RGD-DPGNR/shRNA treated cells. In the case of RPG/shRNA, PEI cannot be degraded within the cell, almost all the fluorescence of YOYO-1 is quenched due to the proximity of the shRNA on the GNR surface [53, 54] . Therefore, a much weaker fluorescence is observed for the RPG/shRNA treated cells. While, the cells incubated with RDG/shRNA complex exhibited much stronger fluorescence, this could be attributed to the dissociation of RDG/shRNA complexes in the reductive intracellular environment, facilitating shRNA release. Glutathione monoester is rapidly internalized by cells and processed into glutathione (GSH) by esterases [55, 56] . When the cells were pretreated with 10 mM monoethyl ester of GSH (GSH-OEt) for 2 h, a slight fluorescence enhancement was observed for the sample treated with RPG/shRNA, which may be attributed to Au-S bond cleavage between GNR and PEI, leading to a small number of shRNAs being liberated from GNR surface.
While, for the RDG/shRNA treated group, the fluorescence profile of YOYO-1 was shifted to the right distinctly and the mean fluorescence intensity was significantly increased after the cells were pre-treated with GSH-OEt.
These results clearly prove the intracellular GSH-triggered rapid degradation of disulfide-containing DSPEI and subsequent a significant release of shRNA in the cytosol.
The intracellular shRNA released in response to GSH was also monitored by confocal laser scanning microscopy (CLSM). To trace the intracellular distribution, shRNA was labeled with YOYO-1, Hoechst 33342
and Lyso Tracker Red DND-99 were used for staining the nuclei and lysosomes, respectively. As shown in the CLSM images (Fig. 4C ), a few green fluorescent spots were observed in the RDG/shRNA treated U-87 MG cells but the fluorescence intensity is significantly increased after the cells were pretreated with GSH-OEt.
Meanwhile, more green fluorescent spots were seen distribution out of lysosomes. These results clearly demonstrate that RDG/shRNA complex nanoparticles could escape from lysosomes and then dissociate and release its shRNA cargo rapidly under reductive intracellular environment.
In vitro GFP silencing
The in vitro RNAi efficiency was detected by model system of shRNA-based reporter GFP knock-down on U-87 MG-GFP cells. Transfection efficiency of RDG based complex was evaluated at a mass ratio of 5, and RPG, DG based complex prepared at mass ratio of 5 and PEI/shRNA complex at N/P ratio of 10 were used as control. All the complex nanoparticles have almost the same surface zeta potential of around +20 mV. For the RNAi experiment, cells were incubated with complexes for 4 h and images were taken after further 42 h culture for GNRs-based complexes and 48 h for PEI/DNA complexes. To determine the silencing efficiency of the complexes, we counted the percentage of GFP-negative cells using flow cytometry, which showed a similar result as above. As shown in Fig. 5C , silencing achieved by PEI/shRNA complex was as high as 81% due to a high cellular uptake of the complex and the proton sponge effect of PEI [31, 32] . Although RGD peptide was grafted on the RPG/shRNA nanoparticles surface, it had an equivalent silencing efficiency compared with that of DG/shRNA complexes (71%-69%). This result could attribute to the reductive triggered degradation of disulfide-containing DSPEI and subsequent dissociation of DG/shRNA complex in the cellular interior, which helped the shRNA to be released over time and thus a high RNAi efficiency. Moreover, grafting of α v β 3 integrin-binding RGD peptide onto DSPEI further enhanced the silencing efficiency (88%) of DG/shRNA, this is mainly due to the efficiently taken up of the complexes by α v β 3
integrins-mediated endocytosis. Therefore, with consideration of the above results, RDG can deliver RNA in a tumor cell targeting and reductive intracellular environment controllable way, and thus it could be considered as a very attractive nanotemplate for gene delivery system.
Additionally, the time-dependent RNAi efficiency of RDG/shRNA complexes in U-87 MG-GFP cells was studied. As shown in Fig. 5D , the GNRs-based complexes had maximum RNAi efficiency after the cells were incubated for 42 h, while, in our study, the corresponding time for PEI/shRNA complexes was 48 h. This is mainly because the GSH-triggered delivery process is different from traditional transfection reagents such as PEI and dendrimers. With a transfection reagent, shRNA must slowly dissociate from the transfection reagent, and finally diffuse in the cytosol. For the RGD targeted and GSH-triggered delivery, the GNRs-based complexes can efficiently and quickly uptaken by the target cells and the shRNA is significantly released into the cytosol due to the intracellular GSH-triggered rapid degradation of disulfide-containing DSPEI. Therefore, it is likely that the RNAi efficiency occurs faster due to the integrins receptor mediated endocytosis of the RDG/shRNA and the effecient shRNA release from the GNRs-based complexes in the cytoplasm.
Biocompatibility of the RDG
In our previous study, the MTT assay against U-87 MG cells indicated that the DSPEI showed significantly lower cytotoxicity than that of PEI-25 kDa, the gold standard of cellular gene transfection reagent. The low cytocompatibility and high cytotoxicity of PEI-25 kDa is probably due to its non-biodegradable nature, high binding and aggregation on the cell surface and internalization, which results in significant necrosis [57] . Since DSPEI is made of the disulfide cross-linked short PEI-1.8 kDa, the disulfide bonds will be cleaved inside cells due to the high concentration of intracellular GSH. As a result, the high molecular weight DSPEI will be converted into low molecular weight PEIs and hence much lower cytotoxicity. Therefore, DSPEI polycation with low cytotoxicity could be a much safer alternative gene carrier over the PEI-25KDa.
The cytotoxicity of the U-87 MG-GFP cells after incubation with the RDG and PEI 25-kDa delivery vectors were investigated by MTT assay. As shown in Fig. 6A , only 55% of cells were survived when treated with PEI.
While, even the concentration of RDG was as high as 25 g/mL (the concentration above the mass ratio of 5), the cell viability still remained at above 85%, revealing that the RDG had a much lower toxic effect on U-87
MG-GFP cells than PEI 25K. To obtain a more convincing data about the cytotoxicity of RDG, cell viability was determined after the cells were treated with RDG/shRNA complex nanoparticles. As shown in Fig. 6B , the cell viability was more than 80% with RDG/shRNA complex at all tested mass ratios. In contrast, cells treated with non-bioreducible RPG nanoparticles and non-degradable PEI nanoparticles showed the lower cell viability of 65% and 58%, respectively. These results further confirmed that RDG had a much lower cytotoxicity than RPG
and PEIs while displayed a higher shRNA transfection efficiency. Therefore, it as appears to be a highly attractive vehicle for shRNA delivery.
Biodistribution in BALB/c mice
To further investigate the tissue distribution of nanoparticles in an in vivo animal model, the GNR-based Fig. 7 , in the case of DSPEI-modified GNR-based complex (DG/shRNA), the gold contents in the tumor was 6.5 % of the total dose, which is likely due to passive targeting via the enhanced permeability and retention (EPR) effect in tumors [58] . The remaining GNRs were found predominantly in the liver and spleen, which is likely due to the high positive charge of DG/shRNA complexes that led to interactions with plasma proteins and cleared by mononuclear phagocyte system (MPS). However, when the GNR PEGylated and modified with RGD peptide, the tissue distribution characteristics of the GNRs were obviously changed. The amount of GNR accumulated in the tumor was significantly higher compared to that of the DG/shRNA group (15.2 v.s. 6.5%), which highlighted the value of RGD modification for targeted tumor accumulation. Notably, the PEGylated RDG/shRNA complex seems to preferentially appear in angiogenesis-related systems, where they show stable circulation in the blood and accumulation in the heart and lung at 12 h post injection. This is mainly due to the coupling of PEG to the composition of the delivery systems, making nanoparticle stealth, can dramatically prevent or minimize serum protein adsorption and avoid uptake by reticuloendothelial system (RES), so as to prolong their residence time in blood. Besides, both the two groups showed a relative higher GNR accumulation in kidney, indicating possible clearance of these GNRs through the renal system. From the analysis above, we can clearly conclude that the PEGylated DG/shRNA complex could stable and long circulating in the blood [58] [59] [60] , especially, the nanoparticles can target and accumulate in tumor tissues, which will deliver more RNA to tumor sites and result in a better RNAi efficiency.
In vivo RNA interference
The fluorescence images of frozen sections of tumors in Fig. 8A and B qualitatively showed the in vivo RNAi effect 48 h after U-87 MG-GFP tumors bearing BALB/c mice were injected with GNR-based complexes and PEI/shRNA complexes. The tumors treated with saline control exhibited strong green fluorescence, while the nanoparticle complexes treated groups showed markedly decreased GFP expression in tumors, especially, the RDG/shRNA complex group which showed almost no visible fluorescence ( Fig. 8B-d) . The quantitative result of RNAi in vivo was further detected by using flow cytometry, which corresponded with the in vitro RNAi study.
As shown in Fig. 8C , GFP silencing efficiency achieved with DG/shRNA complex was about 59%, PEI/shRNA complex revealed a higher efficiency of 72%, and most notably, the RDG/shRNA complex has as high as 82%
GFP silenced in tumors. This result is in good agreement with the above biodistribution and cellular release results, where the complexes are effectively accumulated into the tumor by exploiting the EPR effect and efficient RGD-mediated endocytosis. After which the proton-sponge effects of the DSPEI and GSH content triggers endosomal escape and degradation of the DSPEI, allowing for sufficient release of the encapsulated shRNAs into cytoplasm to achieve high RNAi efficiency. For high molecular weight polyethyleneimine (PEI-25KDa) where despite of high efficacy, its high toxicity and cytotoxicity have greatly restricted its applications, especially under in vivo conditions [61] . More importantly, despite a great number of studies on nonviral RNA carriers at cellular level, few has demonstrated high efficacy like RDG gene carrier in vivo.
Therefore, the experimental data shown here suggested that RDG could be a promising non-viral vector for efficient shRNA delivery.
Conclusion
In conclusion, RDG could tightly condense shRNAs into stable complex nanoparticles. The RDG/shRNA nanoparticle was found to be highly Hoechst 33342 stained nucleus; green: YOYO-1 labeled shRNA; red: Lyso-tracker red stained lysosome. Data are presented as mean ± SD. **: P < 0.01 is considered significantly difference. Time-dependent GFP silencing efficiency of PEI/shRNA and RDG/shRNA complex complexes in U-87
MG-GFP cells. Data displayed as mean ± SD (n = 3). * :P < 0.05, **:P < 0.01. P < 0.05 is considered significantly difference. 
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